Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemotherapy Tolerance in Colon Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed of metastatic colon adenocarcinoma that are going to receive first line chemotherapy treatment in the oncology day hospital.~* Age over 18 years old.~Exclusion Criteria:~* Patients diagnosed of colon cancer are receiving second line chemotherapy.~* Antecedents of other malignant tumors with the exception of basocellular epithelioma.~* Chronic renal failure (Creatinine \> 1.7).~* Previous diabetes mellitus.~* Obesity (IMC \> 30)~* Medical conditions that imply hepatic encephalopathy, or ascites.~* Severe malnutrition according to the classification of the Subjective Global Assessment (SGA) or a BMI \< 16.5.~* Major psychiatric disorder.~* Patients receiving enteral or parenteral nutrition.~* Contraindications for the indication of the nutritional supplement: Galactosemia.~* Seafood or seafood byproducts allergy.~* Patients taking drugs that affect the metabolism (anabolic steroids, orexigenic agents...).~* Absence of the informed consent form signed by the patient.~* Any patient who has disability to comply with the treatment or who has inability according to the researcher.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eicosapentaenoic acid enriched nutritional supplement (Type: EXPERIMENTAL): None
- No supplementation (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).